NEW: Cozy Butter GLP-1 Community! Join Free https://cozybutter.com/ A GLP-1 community where support isn’t at the mercy of the algorithm. - Live GLP-1 support groups - Live support groups and social events - Health coaching and expert Q&As - Cooking, movement, and stress-management classes - Practical GLP-1 tools and guidance (water, protein, side effect management, etc.) - A dedicated community beyond the algorithm
The World Has More GLP-1s but Who Can Afford Them? Part 1
This week’s GLP-1 news had us thinking about access. Oral Wegovy launched in Germany, and Hims & Hers expanded its GLP-1 services into Australia. But in the U.S., PepsiCo announced it would cut obesity medication coverage while 600,000 people signed up for the new Medicare GLP-1 Bridge program. That is less than 1% of all Medicare beneficiaries, although we still do not know how many were approved or received medication.
Four years after Mounjaro launched, are GLP-1s becoming easier to find but harder to get covered? It felt like the right time to revisit this Season 4 conversation with Dr. Michael “Mick” Crotty and Belinda Hogan about GLP-1 access, obesity care and weight bias around the world.
In Part 1, we discuss: • How fat functions in the body and why it is considered an organ • GLP-1 access, costs and treatment criteria in Ireland • Which obesity medications were available in Ireland • Differences between obesity care in Ireland and the United States • Weight bias in healthcare and society • Why obesity requires medical care, not more blame
Dr. Crotty is a GP, co-founder and clinical lead of My Best Weight in Ireland. Belinda shares her lived experience using GLP-1 medication and navigating obesity care.
CONNECT WITH OUR GUESTS
Dr. Michael “Mick” Crotty My Best Weight https://www.mybestweight.ie/ Instagram https://www.instagram.com/mybestweight.ie/ LinkedIn https://ie.linkedin.com/in/drmichaelcrotty
Belinda Hogan Instagram https://www.instagram.com/mid.life.insights/ The Dose with Paddy and Belinda https://linktr.ee/TheDosePodcast
SOURCES Oral Wegovy launches in Germany https://www.reuters.com/legal/litigation/novo-nordisk-launches-wegovy-weight-loss-pill-germany-2026-09-01/ Hims & Hers expands its GLP-1 services into Australia https://www.reuters.com/business/healthcare-pharmaceuticals/hims-hers-offers-glp-1-weight-loss-drugs-mens-health-treatments-australia-2026-08-31/ 600,000 people sign up for the Medicare obesity drug program https://www.reuters.com/legal/litigation/600000-seniors-have-signed-up-obesity-drugs-under-new-medicare-program-2026-08-31/ Employer GLP-1 coverage fell in 2026 https://www.reuters.com/legal/litigation/more-us-employers-drop-weight-loss-drugs-2027-healthcare-costs-increase-2026-08-25/ PepsiCo and other employers cut GLP-1 coverage https://abcnews.com/Health/companies-offering-coverage-glp-1-weight-loss-drugs/story?id=135999790 Medicare enrollment data https://data.cms.gov/summary-statistics-on-beneficiary-enrollment/medicare-and-medicaid-reports/medicare-monthly-enrollment
Podden och tillhörande omslagsbild på den här sidan tillhör
Kim Carlos. Innehållet i podden är skapat av Kim Carlos och inte av,
eller tillsammans med, Poddtoppen.
